Ophthalmology Times11d
FDA accepts new drug application for low-dose atropine from Sydnexis
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
Monthly Prescribing Reference12d
Low-Dose Atropine Eye Drops Under Review for Pediatric Myopia
SYD-101 contains a low dose of atropine sulfate, an antimuscarinic agent ... Study is the largest clinical study ever completed for the treatment of progression of pediatric myopia, enrolling more ...
Healio11d
FDA accepts new drug application for SYD-101 to treat pediatric myopia progression
The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...